Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Xiaozhong Qian,Meletios A Dimopoulos,Michael Amatangelo,Chad Bjorklund,Katja C Weisel,Enrique M Ocio,Xin Yu,Teresa Peluso,Lars Sternas,Mohamed Zaki,Philippe Moreau,Anjan Thakurta

doi:10.1182/blood.v130.suppl_1.3109.3109

Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Xiaozhong Qian, Meletios A Dimopoulos + Show 10 more

https://doi.org/10.1182/blood.v130.suppl_1.3109.3109

Copy DOI

Journal: Blood

Publication Date: Jun 25, 2021

Affiliation: Bristol-Myers Squibb (Switzerland), Universitätsklinikum Tübingen, Universidad de Salamanca, National and Kapodistrian University of Athens

#Celgene Corporation #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Full Text